The prevalence of relapses in advanced squamous cell head and neck cancer (SCHNC) is significant, and so is treatment morbidity. There is persistent need for reliable biomarkers in order to better personalize treatment. The purpose of the present study was to ... ...

请注册登录后继续浏览